Return to homepagePandemic Pact

Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3R01CA201189-05S1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $168,429

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    Nina Bhardwaj

  • Research Location

    United States of America

  • Lead Research Institution

    Icahn School Of Medicine At Mount Sinai

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The pandemic caused by SARS-CoV-2 has killed 430,000 people worldwide in the span of 6 months whichoverall place cancer patients at a higher risk of severe illness and death if infected, although differences betweendistinct therapy regimens are possible (e.g. chemotherapy vs. immunotherapy vs. palliation). Cancer patientswho have recovered from COVID-19 may need to resume treatment, including immunotherapy for their diseaseeven though the repercussions of this infection on their immune systems are unknown. This project will determineif cancer patients who have recovered from COVID-19 have NK cells with different functionality than cancerpatients who were not infected, and whether these phenotypes have an impact on the overall response rate andsurvival of this population.